English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of the current investigation was to develop a Sustained release tablet of Donepezil Hydrochloride using non- gelling polymer in order to overcome the problem of dose dumping. Viscarin GP-209 was used as a non-gelling release modifying agent. The formulated granule blends were evaluated for powder properties. Prepared tablets were subjected to post compression evaluations. In-vitro dissolution studies were carried out in 3 different dissolution profiles. Profile1: 0.1 N Hcl medium, Profile 2: pH 5.5 sodium phosphate buffer medium and Profile3: in 0.1 N Hcl for 2hrs and in 6.8 pH sodium phosphate buffer medium using the USP Type 2 apparatus as per the FDA guidelines. The dissolution data was fitted into various kinetic models to determine the release mechanism and mean dissolution time. Formulation F6 was considered as optimized as it showed similar drug release pattern with that of innovator immediate release formulation and similarity factor (f2) of 82. F6 formulation was found to be stable up to 3 months of stability testing at 40 o c / 75%RH.

Preparation and In-Vitro Evaluation of Donepezil Hydrochloride Sustained Release Matrix Tablets Using Non-Gelling Polymer